azd6553

AZD6553 is an investigational oral small molecule drug developed by AstraZeneca for the treatment of chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. The drug was designed as a neutrophil elastase inhibitor, aiming to reduce the activity of this protease implicated in lung tissue damage and inflammation associated with COPD. By inhibiting neutrophil elastase, AZD6553 was intended to control symptoms, reduce exacerbations, and slow disease progression in COPD patients. Clinical development included Phase 1 studies assessing safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and patients with moderate to severe COPD. However, development has been discontinued[1][2][3][4].

Other names

AZD-6553AZD6553AZD 6553